Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
BackgroundWhile neoadjuvant chemoimmunotherapy shows promise for locally advanced esophageal squamous cell carcinoma (ESCC), optimal regimen selection remains challenging. This study compares perioperative outcomes between camrelizumab- and tislelizumab-based neoadjuvant chemoimmunotherapy in ESCC.M...
Saved in:
| Main Authors: | Qi Zhao, Yusen Yuan, Tongxin Xu, Ningning Yan, Fei Li, Juntao Lu, Ming He, Zhaoyang Yan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544739/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01) -
Indications for neoadjuvant radiation in esophageal adenocarcinoma: Times are changingCentral Message
by: Stephanie G. Worrell, MD, FACS
Published: (2024-06-01) -
Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01) -
Perioperative outcomes of esophagectomy after doublet versus docetaxel‐based triplet neoadjuvant chemotherapy in older patients: A nationwide inpatient database study in Japan
by: Yuki Hirano, et al.
Published: (2025-07-01) -
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study
by: Zhenyu Lin, et al.
Published: (2025-05-01)